Meissner Announces Award Of $13.4 Million Contract From BARDA

Meissner Filtration Products announced today the award of a $13.4 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to facilitate expedited expansion of their production capacity for products critical to COVID-19 vaccine and therapeutics manufacturing.

“Meissner has experienced substantial demand for our products associated with federally funded vaccine and therapeutics manufacturing efforts,” stated Christopher Meissner, CEO of Meissner Filtration Products. “It has been incredibly fulfilling for our organization to be able to make a direct impact fighting this pandemic and this contract serves to amplify and accelerate those efforts.”

Meissner will be expanding its Camarillo, California, manufacturing campus by making a significant investment alongside the BARDA award to include additional cleanroom manufacturing space, implementing advanced inventory management systems and adding support areas to augment capacity.

“While we have seen increased demand on the basis of COVID-19 vaccines and therapeutics, our products are also a key piece in the development and manufacture of other lifesaving medicines so it’s critical that we able to support all of our customers through this period and in the future,” said Max Blomberg, Executive Director of Operations. “This expansion, which will provide a substantial capacity augmentation for our Camarillo campus, is just the latest in our continuing work to ensure we scale with our clients’ needs.”

This project has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (DHHS), under Contract No. 75A50121C00028.

About Meissner Filtration Products – Meissner manufactures advanced microfiltration products and single-use systems for critical pharmaceutical and biopharmaceutical applications, such as sterilization of injectable drugs, and processing of life-enhancing/life-saving therapies. The company is a critical supplier to manufacturers of COVID-19 vaccines, therapies, treatments, and associated test kits. Meissner’s manufacturing campuses include a headquarters location in Camarillo, California, USA, and a European manufacturing location in Castlebar, Ireland. Their product portfolios are built upon a solid foundation of quality, operational excellence and technical expertise, which allows delivery of high performance products and technical support services for their clients’ critical applications. For more information about Meissner, please visit www.meissner.com.